The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancer

2021 ◽  
Author(s):  
Mike Wenzel ◽  
Charles Dariane ◽  
Fred Saad ◽  
Pierre I. Karakiewicz ◽  
Philipp Mandel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Prostate Specific Antigen ◽  
Biochemical Recurrence ◽  
Specific Antigen ◽  
Mortality Rates ◽  
Localized Prostate Cancer ◽  
The Impact

The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate cancer

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4503-4503
Author(s):  
P. L. Nguyen ◽  
R. Whittington ◽  
S. Koo ◽  
D. Schultz ◽  
K. B. Cote ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Localized Prostate Cancer ◽  
The Impact

The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate cancer

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4503-4503 ◽  
Author(s):  
P. L. Nguyen ◽  
R. Whittington ◽  
S. Koo ◽  
D. Schultz ◽  
K. B. Cote ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Localized Prostate Cancer ◽  
The Impact

Biochemical Recurrence after Radical Prostatectomy

2018 ◽  
Author(s):  
Dunia Khaled ◽  
Scott Delacroix ◽  
Brian Chapin
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Lymph Node ◽  
Radical Prostatectomy ◽  
Prostate Specific Antigen ◽  
Lymph Node Dissection ◽  
Biochemical Recurrence ◽  
Specific Antigen ◽  
Node Dissection ◽  
Salvage Lymph Node Dissection

After receiving local treatment, many patients will develop a biochemical recurrence (BCR) in the absence of detectable distant disease (cM0) and comprise a significant proportion (20.1%) of prostate cancer disease states. The natural history of patients with BCR ranges from those with indolent, nonprogressive, slow prostate-specific antigen (PSA)-only progression to those ultimately destined to develop metastases and progress to a cancer-specific death. Pathologic predictors of BCR, clinical progression, and cancer-specific mortality are well established in the literature, although multiple novel predictors are emerging, which are highlighted. Traditional imaging cannot reliably distinguish local versus distant microscopic metastasis at the PSA levels that have been shown to confer survival advantage for salvage radiation therapy. We review past and present imaging standards and discuss novel imaging modalities, which may improve staging and offer opportunity for novel salvage therapies, including salvage lymph node dissection and stereotactic beam radiation therapy. With an emphasis on BCR after radical prostatectomy, both curative and palliative treatments are reviewed. This review contains 7 figures, 6 tables and 73 references Key words: biochemical recurrence, clinically undetectable metastases, molecular imaging, monitoring treatment response, prostate cancer, radical prostatectomy, rising prostate-specific antigen, salvage lymph node dissection, salvage radiation  

scholarly journals Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer

Cancer ◽  
2007 ◽  
Vol 109 (8) ◽  
pp. 1493-1498 ◽  
Author(s):  
Jason A. Efstathiou ◽  
Ming-Hui Chen ◽  
Andrew A. Renshaw ◽  
Marian J. Loffredo ◽  
Anthony V. D'Amico
Keyword(s):  
Prostate Cancer ◽  
Body Mass Index ◽  
Radiation Therapy ◽  
Prostate Specific Antigen ◽  
Body Mass ◽  
Specific Antigen ◽  
Localized Prostate Cancer ◽  
Androgen Suppression
Sign in / Sign up

Export Citation Format

Share Document